Pfizer traded up 1.41% on Tuesday, hitting $28.08. Pfizer has a 52-week low of $21.19 and a 52-week high of $27.84. The stock’s 50-day moving average is currently $27.13. The company has a market cap of $206.7 billion and a price-to-earnings ratio of 14.30.
Pfizer last announced its earnings results on Tuesday, January 29th. The company reported $0.47 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.44 by $0.03. The company had revenue of $15.10 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was down 6.6% on a year-over-year basis. Pfizer has set its FY13 guidance at $2.20-2.30 EPS. Analysts expect that Pfizer will post $2.28 EPS for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Bank of America reiterated a “buy” rating on shares of Pfizer in a research note to investors on Monday. They now have a $30.00 price target on the stock, up previously from $29.00. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Pfizer in a research note to investors on Monday, February 25th. They now have a $31.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pfizer in a research note to investors on Friday, February 15th. They now have a $31.00 price target on the stock.
Thirteen analysts have rated the stock with a buy rating, four have assigned an overweight rating, and seven have assigned a hold rating to the stock. The company presently has an average rating of “overweight” and a consensus price target of $29.67.
Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health and Consumer Healthcare, and Nutrition.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.